About northwest biotherapeutics - NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.
NWBO At a Glance
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane
Bethesda, Maryland 20814
| Phone | 1-240-497-9024 | Revenue | 1.38M | |
| Industry | Pharmaceuticals: Major | Net Income | -83,778,000.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
NWBO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 246.964 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.547 |
| Enterprise Value to Sales | 305.41 |
| Total Debt to Enterprise Value | 0.16 |
NWBO Efficiency
| Revenue/Employee | 55,280.00 |
| Income Per Employee | -3,351,120.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.05 |
NWBO Liquidity
| Current Ratio | 0.059 |
| Quick Ratio | 0.059 |
| Cash Ratio | 0.032 |
NWBO Profitability
| Gross Margin | -47.902 |
| Operating Margin | -4,812.446 |
| Pretax Margin | -6,062.084 |
| Net Margin | -6,062.084 |
| Return on Assets | -306.033 |
| Return on Equity | N/A |
| Return on Total Capital | 730.983 |
| Return on Invested Capital | N/A |
NWBO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -588.43 |
| Total Debt to Total Assets | 251.576 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -285.612 |